Establishment of Patient-Derived Models of Renal Cell Carcinoma to Study Metabolism and Develop Relevant Clinical Biomarkers

Renuka Sriram¹, Kayvan R. Keshari¹, Mark Van Criekinge¹, John Kurhanewicz¹, David M. Wilson¹, Donna M. Peehl², Zhen J. Wang¹

Renal cell carcinomas (RCCs) are a heterogeneous group of tumors with a wide range of aggressiveness. There is a current lack of noninvasive biomarkers that can confidently predict the behavior of RCCs to guide treatment selection and to monitor treatment response. Development of clinically relevant biomarkers of RCC aggressiveness and response to novel therapeutics requires robust models that recapitulate the human situation. The purpose of this study is to establish both an ex vivo and an in vivo model of RCCs using patient-derived tissue slices for metabolism studies in conjunction with hyperpolarized (HP) ¹³C MR.